

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Goddard et al.

Attorney's Docket No: 39780-2630P1C4

Serial No: 09/978,191

Group Art Unit: 1646

Filed: October 15, 2001

Examiner: O'Hara, Eileen B.

For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**DECLARATION OF AUDREY GODDARD, Ph.D.,
PAUL J. GODOWSKI, Ph.D., AUSTIN GURNEY, Ph.D., MARGARET A. ROY
and WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131**

We, Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., Margaret Roy and William I. Wood, Ph.D. do hereby declare and say as follows:


1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by Holtzman *et al.*, U.S. Published Patent Application 20020028508, with effective priority date April 23, 1998 (09/065,363), and Sheppard *et al.*, U.S. Published Patent Application 20030166907, with effective priority date June 18, 1997 (09/050,143)
3. The polypeptide comprising the amino acid sequence of residues 35-273 of SEQ ID NO:506 and the nucleic acid sequence of nucleotides 603-1220 of SEQ ID NO:505 in the above-identified application in the United States were sequenced and cloned prior to June 18, 1997.
4. At the time the above polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA encoding the polypeptide comprising the amino acid sequence of residues 35-273 of SEQ ID NO:506.

5. At the time the above polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, was responsible for overseeing the sequencing of nucleotides encoding novel polypeptides, including the polypeptide having the amino acid sequence of residues 35-273 of SEQ ID NO: 506 in the above-identified application.
6. At the time the nucleotide encoding the above polypeptide was cloned and sequenced, one of the inventors, William I. Wood, was responsible for overseeing the homology searches for novel polypeptides, including that for the polypeptide having the amino acid sequence of residues 35-273 of SEQ ID NO: 506 in the above-identified application.
7. The PRO213 polypeptide shown in SEQ ID NO:2 is encoded by a cDNA sequence referred to as DNA30943-1163 and shown in Figure 2 of the above-identified application.
8. A cDNA sequence DNA30943-1163 is identified as SEQ ID NO:1 and shown in Figure 1 of the above-identified application.
9. The PRO213 nucleic acid sequence was found to contain sequence errors. Therefore, the PRO213 nucleic acid sequence was resequenced and designated as 213-1 nucleic acid sequence and the translated polypeptide was designated as the PRO213-1 polypeptide.
10. The PRO213-1 polypeptide shown in SEQ ID NO:506 is encoded by a cDNA sequence referred to as DNA30943-1-1163-1 and shown in Figure 213 of the above-identified application..
11. A cDNA sequence DNA30943-1-1163-1 is identified as SEQ ID NO:505 and shown in Figure 212 of the above-identified application.
12. Copies of the pages from the GSeqEdit database and GenenGenes database which report the cloning, sequencing and functional data for the PRO213 and PRO213-1 polypeptide sequences, including its homology to human gas6, as well as the cloning, and sequencing data for the nucleic acid sequence encoding the PRO213 and PRO213-1 polypeptides are attached to this declaration (with the dates redacted) as Exhibit A.

13. The GSeqEdit report shows the full-length nucleic acid sequence for DNA30943-1-1163-1 and the full-length PRO213-1 polypeptide encoded by DNA30943-1-1163-1. The full-length nucleic acid sequence for PRO213-1 (DNA30943-1-1163-1) shown in the report includes the sequence corrections made to PRO213 (DNA30943-1163) indicated below the sequence, for example, as seen on page 5 of the report. The full-length nucleic acid sequence for PRO213 (DNA30943-1163) is the sequence shown in the GSeqEdit report without the indicated corrections.
14. The amino acid sequence of residues 1-49 of PRO213 is shown in GSeqEdit report on pages 4-5. The amino acid sequence of PRO213-1 shown in GSeqEdit report starts on page 4 and continues onto the following pages. On page 5, the top sequence is the PRO213 polypeptide sequence and the bottom sequence is the PRO213-1 polypeptide sequence.
15. The amino acid sequence starting on page 6 of the GSeqEdit is identical for both the PRO213 and PRO213-1 polypeptides. Amino acid residue number 35, shown on page 6 of the GSeqEdit report, indicates the continuous numbering of PRO213-1 polypeptide sequence from the previous page. The first amino acid on page 6 corresponds to amino acid 57 of the PRO213 polypeptide.
16. The amino acid sequence of residues 35-273 of SEQ ID NO:506 shown in Figure 213 of the above-identified application is 239 amino acids long, and is identical to the amino acid sequence of residues 57-295 of SEQ ID NO:2 shown in Figure 2 of the above-identified application.
17. The nucleic acid sequence encoding residues 35-273 of SEQ ID NO: 506 comprises residues 501-1220 of SEQ ID NO:505 in Figure 212 of the above-identified application. The nucleic acid sequence comprising residues 501-1220 of SEQ ID NO:505 is 720 nucleotides long and it includes a stop codon.
18. The portion of the PRO213 polypeptide, which is identical to the portion of the PRO213-1 polypeptide encoded by the nucleic acid sequence comprising residues 501-1220 of SEQ ID NO:505, is significantly homologous with the human growth arrest-specific 6 (gas6) protein.

19. Both DNA30943-1163 cDNA sequence and the PRO213 polypeptide encoded by DNA30943-1163 were obtained prior to June 18, 1997. Furthermore, the homology of PRO213 to human gas6 was obtained prior to June 18, 1997.
20. The DNA sequence of nucleotides 606 to 1223 of SEQ ID NO:1 is identical to nucleotides 603 to 1220 of DNA30943-1-1163-1 sequence shown in the GSeqEdit report. Further, the DNA sequences of nucleotides 606 to 1223 of SEQ ID NO:1 and nucleotides 603 to 1220 of DNA30943-1-1163-1 shown in the GSeqEdit report are identical to that of nucleotides 603-1220 of SEQ ID NO:505 disclosed in the above-identified application.
21. The beginning of the cDNA sequence corresponding to nucleotides 501-1220 of SEQ ID NO:505 in the above-identified application is shown on page 6 of the GSeqEdit database report. The location of nucleotide 501 of SEQ ID:505, which corresponds to nucleotide 501 of DNA30943-1-1163-1 shown in the GSeqEdit report, is marked with an arrow. The location of nucleotide 603 of SEQ ID:505, which corresponds to nucleotide 603 of DNA30943-1-1163-1 shown on page 7 of the GSeqEdit report, is marked with an arrow. The location of the nucleotide 1220 of SEQ ID NO:505, which corresponds to nucleotide 1220 of DNA30943-1-1163-1 shown on page 12 of the GSeqEdit report, is marked with an arrow.
22. The amino acid residues in the GSeqEdit report which correspond to residues 35 to 273 of SEQ ID NO: 506 are shown starting on page 6 (indicated by an arrow) to page 12 of the report.
23. Exhibit A clearly shows that amino acids residues 35 to 273 of SEQ ID NO: 506 and the nucleic acid residues 603-1220 of SEQ ID NO: 505 disclosed in the above-identified application, as well as the homology of the polypeptide to human gas6, were obtained prior to June 18, 1997.

24. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.



Audrey Goddard, Ph.D.

5/8/05

Date

Paul J. Godowski, Ph.D.

Date

Austin Gurney, Ph.D.

Date

Margaret A. Roy

Date

William I. Wood, Ph.D.

Date

SV 2094833 v1
4/29/05 10:13 AM (39780.2630)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Goddard et al.

Attorney's Docket No: 39780-2630P1C4

Serial No: 09/978,191

Group Art Unit: 1646

Filed: October 15, 2001

Examiner: O'Hara, Eileen B.

For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**DECLARATION OF AUDREY GODDARD, Ph.D.,
PAUL J. GODOWSKI, Ph.D., AUSTIN GURNEY, Ph.D., MARGARET A. ROY
and WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131**

We, Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., Margaret Roy and William I. Wood, Ph.D. do hereby declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by Holtzman *et al.*, U.S. Published Patent Application 20020028508, with effective priority date April 23, 1998 (09/065,363), and Sheppard *et al.*, U.S. Published Patent Application 20030166907, with effective priority date June 18, 1997 (09/050,143)
3. The polypeptide comprising the amino acid sequence of residues 35-273 of SEQ ID NO:506 and the nucleic acid sequence of nucleotides 603-1220 of SEQ ID NO:505 in the above-identified application in the United States were sequenced and cloned prior to June 18, 1997.
4. At the time the above polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA encoding the polypeptide comprising the amino acid sequence of residues 35-273 of SEQ ID NO:506.

5. At the time the above polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, was responsible for overseeing the sequencing of nucleotides encoding novel polypeptides, including the polypeptide having the amino acid sequence of residues 35-273 of SEQ ID NO: 506 in the above-identified application.
6. At the time the nucleotide encoding the above polypeptide was cloned and sequenced, one of the inventors, William I. Wood, was responsible for overseeing the homology searches for novel polypeptides, including that for the polypeptide having the amino acid sequence of residues 35-273 of SEQ ID NO: 506 in the above-identified application.
7. The PRO213 polypeptide shown in SEQ ID NO:2 is encoded by a cDNA sequence referred to as DNA30943-1163 and shown in Figure 2 of the above-identified application.
8. A cDNA sequence DNA30943-1163 is identified as SEQ ID NO:1 and shown in Figure 1 of the above-identified application.
9. The PRO213 nucleic acid sequence was found to contain sequence errors. Therefore, the PRO213 nucleic acid sequence was resequenced and designated as 213-1 nucleic acid sequence and the translated polypeptide was designated as the PRO213-1 polypeptide.
10. The PRO213-1 polypeptide shown in SEQ ID NO:506 is encoded by a cDNA sequence referred to as DNA30943-1-1163-1 and shown in Figure 213 of the above-identified application..
11. A cDNA sequence DNA30943-1-1163-1 is identified as SEQ ID NO:505 and shown in Figure 212 of the above-identified application.
12. Copies of the pages from the GSeqEdit database and GenenGenes database which report the cloning, sequencing and functional data for the PRO213 and PRO213-1 polypeptide sequences, including its homology to human gas6, as well as the cloning, and sequencing data for the nucleic acid sequence encoding the PRO213 and PRO213-1 polypeptides are attached to this declaration (with the dates redacted) as Exhibit A.


13. The GSeqEdit report shows the full-length nucleic acid sequence for DNA30943-1-1163-1 and the full-length PRO213-1 polypeptide encoded by DNA30943-1-1163-1. The full-length nucleic acid sequence for PRO213-1 (DNA30943-1-1163-1) shown in the report includes the sequence corrections made to PRO213 (DNA30943-1163) indicated below the sequence, for example, as seen on page 5 of the report. The full-length nucleic acid sequence for PRO213 (DNA30943-1163) is the sequence shown in the GSeqEdit report without the indicated corrections.
14. The amino acid sequence of residues 1-49 of PRO213 is shown in GSeqEdit report on pages 4-5. The amino acid sequence of PRO213-1 shown in GSeqEdit report starts on page 4 and continues onto the following pages. On page 5, the top sequence is the PRO213 polypeptide sequence and the bottom sequence is the PRO213-1 polypeptide sequence.
15. The amino acid sequence starting on page 6 of the GSeqEdit is identical for both the PRO213 and PRO213-1 polypeptides. Amino acid residue number 35, shown on page 6 of the GSeqEdit report, indicates the continuous numbering of PRO213-1 polypeptide sequence from the previous page. The first amino acid on page 6 corresponds to amino acid 57 of the PRO213 polypeptide.
16. The amino acid sequence of residues 35-273 of SEQ ID NO:506 shown in Figure 213 of the above-identified application is 239 amino acids long, and is identical to the amino acid sequence of residues 57-295 of SEQ ID NO:2 shown in Figure 2 of the above-identified application.
17. The nucleic acid sequence encoding residues 35-273 of SEQ ID NO: 506 comprises residues 501-1220 of SEQ ID NO:505 in Figure 212 of the above-identified application. The nucleic acid sequence comprising residues 501-1220 of SEQ ID NO:505 is 720 nucleotides long and it includes a stop codon.
18. The portion of the PRO213 polypeptide, which is identical to the portion of the PRO213-1 polypeptide encoded by the nucleic acid sequence comprising residues 501-1220 of SEQ ID NO:505, is significantly homologous with the human growth arrest-specific 6 (gas6) protein.

19. Both DNA30943-1163 cDNA sequence and the PRO213 polypeptide encoded by DNA30943-1163 were obtained prior to June 18, 1997. Furthermore, the homology of PRO213 to human gas6 was obtained prior to June 18, 1997.
20. The DNA sequence of nucleotides 606 to 1223 of SEQ ID NO:1 is identical to nucleotides 603 to 1220 of DNA30943-1-1163-1 sequence shown in the GSeqEdit report. Further, the DNA sequences of nucleotides 606 to 1223 of SEQ ID NO:1 and nucleotides 603 to 1220 of DNA30943-1-1163-1 shown in the GSeqEdit report are identical to that of nucleotides 603-1220 of SEQ ID NO:505 disclosed in the above-identified application.
21. The beginning of the cDNA sequence corresponding to nucleotides 501-1220 of SEQ ID NO:505 in the above-identified application is shown on page 6 of the GSeqEdit database report. The location of nucleotide 501 of SEQ ID:505, which corresponds to nucleotide 501 of DNA30943-1-1163-1 shown in the GSeqEdit report, is marked with an arrow. The location of nucleotide 603 of SEQ ID:505, which corresponds to nucleotide 603 of DNA30943-1-1163-1 shown on page 7 of the GSeqEdit report, is marked with an arrow. The location of the nucleotide 1220 of SEQ ID NO:505, which corresponds to nucleotide 1220 of DNA30943-1-1163-1 shown on page 12 of the GSeqEdit report, is marked with an arrow.
22. The amino acid residues in the GSeqEdit report which correspond to residues 35 to 273 of SEQ ID NO: 506 are shown starting on page 6 (indicated by an arrow) to page 12 of the report.
23. Exhibit A clearly shows that amino acids residues 35 to 273 of SEQ ID NO: 506 and the nucleic acid residues 603-1220 of SEQ ID NO: 505 disclosed in the above-identified application, as well as the homology of the polypeptide to human gas6, were obtained prior to June 18, 1997.

24. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Audrey Goddard, Ph.D.

Date



Paul J. Godowski, Ph.D.

5/15/05

Date

Austin Gurney, Ph.D.

Date

Margaret A. Roy

Date

William I. Wood, Ph.D.

Date

SV 2094833 v1
4/29/05 10:13 AM (39780.2630)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Goddard et al. Attorney's Docket No: 39780-2630P1C4
Serial No: 09/978,191 Group Art Unit: 1646
Filed: October 15, 2001 Examiner: O'Hara, Eileen B.
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**DECLARATION OF AUDREY GODDARD, Ph.D.,
PAUL J. GODOWSKI, Ph.D., AUSTIN GURNEY, Ph.D., MARGARET A. ROY
and WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131**

We, Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., Margaret Roy and William I. Wood, Ph.D. do hereby declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by Holtzman *et al.*, U.S. Published Patent Application 20020028508, with effective priority date April 23, 1998 (09/065,363), and Sheppard *et al.*, U.S. Published Patent Application 20030166907, with effective priority date June 18, 1997 (09/050,143)
3. The polypeptide comprising the amino acid sequence of residues 35-273 of SEQ ID NO:506 and the nucleic acid sequence of nucleotides 603-1220 of SEQ ID NO:505 in the above-identified application in the United States were sequenced and cloned prior to June 18, 1997.
4. At the time the above polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA encoding the polypeptide comprising the amino acid sequence of residues 35-273 of SEQ ID NO:506.

5. At the time the above polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, was responsible for overseeing the sequencing of nucleotides encoding novel polypeptides, including the polypeptide having the amino acid sequence of residues 35-273 of SEQ ID NO: 506 in the above-identified application.
6. At the time the nucleotide encoding the above polypeptide was cloned and sequenced, one of the inventors, William I. Wood, was responsible for overseeing the homology searches for novel polypeptides, including that for the polypeptide having the amino acid sequence of residues 35-273 of SEQ ID NO: 506 in the above-identified application.
7. The PRO213 polypeptide shown in SEQ ID NO:2 is encoded by a cDNA sequence referred to as DNA30943-1163 and shown in Figure 2 of the above-identified application.
8. A cDNA sequence DNA30943-1163 is identified as SEQ ID NO:1 and shown in Figure 1 of the above-identified application.
9. The PRO213 nucleic acid sequence was found to contain sequence errors. Therefore, the PRO213 nucleic acid sequence was resequenced and designated as 213-1 nucleic acid sequence and the translated polypeptide was designated as the PRO213-1 polypeptide.
10. The PRO213-1 polypeptide shown in SEQ ID NO:506 is encoded by a cDNA sequence referred to as DNA30943-1-1163-1 and shown in Figure 213 of the above-identified application..
11. A cDNA sequence DNA30943-1-1163-1 is identified as SEQ ID NO:505 and shown in Figure 212 of the above-identified application.
12. Copies of the pages from the GSeqEdit database and GenenGenes database which report the cloning, sequencing and functional data for the PRO213 and PRO213-1 polypeptide sequences, including its homology to human gas6, as well as the cloning, and sequencing data for the nucleic acid sequence encoding the PRO213 and PRO213-1 polypeptides are attached to this declaration (with the dates redacted) as Exhibit A.

13. The GSeqEdit report shows the full-length nucleic acid sequence for DNA30943-1-1163-1 and the full-length PRO213-1 polypeptide encoded by DNA30943-1-1163-1. The full-length nucleic acid sequence for PRO213-1 (DNA30943-1-1163-1) shown in the report includes the sequence corrections made to PRO213 (DNA30943-1163) indicated below the sequence, for example, as seen on page 5 of the report. The full-length nucleic acid sequence for PRO213 (DNA30943-1163) is the sequence shown in the GSeqEdit report without the indicated corrections.
14. The amino acid sequence of residues 1-49 of PRO213 is shown in GSeqEdit report on pages 4-5. The amino acid sequence of PRO213-1 shown in GSeqEdit report starts on page 4 and continues onto the following pages. On page 5, the top sequence is the PRO213 polypeptide sequence and the bottom sequence is the PRO213-1 polypeptide sequence.
15. The amino acid sequence starting on page 6 of the GSeqEdit is identical for both the PRO213 and PRO213-1 polypeptides. Amino acid residue number 35, shown on page 6 of the GSeqEdit report, indicates the continuous numbering of PRO213-1 polypeptide sequence from the previous page. The first amino acid on page 6 corresponds to amino acid 57 of the PRO213 polypeptide.
16. The amino acid sequence of residues 35-273 of SEQ ID NO:506 shown in Figure 213 of the above-identified application is 239 amino acids long, and is identical to the amino acid sequence of residues 57-295 of SEQ ID NO:2 shown in Figure 2 of the above-identified application.
17. The nucleic acid sequence encoding residues 35-273 of SEQ ID NO: 506 comprises residues 501-1220 of SEQ ID NO:505 in Figure 212 of the above-identified application. The nucleic acid sequence comprising residues 501-1220 of SEQ ID NO:505 is 720 nucleotides long and it includes a stop codon.
18. The portion of the PRO213 polypeptide, which is identical to the portion of the PRO213-1 polypeptide encoded by the nucleic acid sequence comprising residues 501-1220 of SEQ ID NO:505, is significantly homologous with the human growth arrest-specific 6 (gas6) protein.

19. Both DNA30943-1163 cDNA sequence and the PRO213 polypeptide encoded by DNA30943-1163 were obtained prior to June 18, 1997. Furthermore, the homology of PRO213 to human gas6 was obtained prior to June 18, 1997.
20. The DNA sequence of nucleotides 606 to 1223 of SEQ ID NO:1 is identical to nucleotides 603 to 1220 of DNA30943-1-1163-1 sequence shown in the GSeqEdit report. Further, the DNA sequences of nucleotides 606 to 1223 of SEQ ID NO:1 and nucleotides 603 to 1220 of DNA30943-1-1163-1 shown in the GSeqEdit report are identical to that of nucleotides 603-1220 of SEQ ID NO:505 disclosed in the above-identified application.
21. The beginning of the cDNA sequence corresponding to nucleotides 501-1220 of SEQ ID NO:505 in the above-identified application is shown on page 6 of the GSeqEdit database report. The location of nucleotide 501 of SEQ ID:505, which corresponds to nucleotide 501 of DNA30943-1-1163-1 shown in the GSeqEdit report, is marked with an arrow. The location of nucleotide 603 of SEQ ID:505, which corresponds to nucleotide 603 of DNA30943-1-1163-1 shown on page 7 of the GSeqEdit report, is marked with an arrow. The location of the nucleotide 1220 of SEQ ID NO:505, which corresponds to nucleotide 1220 of DNA30943-1-1163-1 shown on page 12 of the GSeqEdit report, is marked with an arrow.
22. The amino acid residues in the GSeqEdit report which correspond to residues 35 to 273 of SEQ ID NO: 506 are shown starting on page 6 (indicated by an arrow) to page 12 of the report.
23. Exhibit A clearly shows that amino acids residues 35 to 273 of SEQ ID NO: 506 and the nucleic acid residues 603-1220 of SEQ ID NO: 505 disclosed in the above-identified application, as well as the homology of the polypeptide to human gas6, were obtained prior to June 18, 1997.

24. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.

Date



Austin Gurney, Ph.D.

5/5/05

Date


Margaret A. Roy

Date

William I. Wood, Ph.D.

Date

SV 2094833 v1
5/1/05 12:37 PM (39780.2630)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Goddard et al.

Attorney's Docket No: 39780-2630P1C4

Serial No: 09/978,191

Group Art Unit: 1646

Filed: October 15, 2001

Examiner: O'Hara, Eileen B.

For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

DECLARATION OF AUDREY GODDARD, Ph.D.,
PAUL J. GODOWSKI, Ph.D., AUSTIN GURNEY, Ph.D., MARGARET A. ROY
and WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131

We, Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., Margaret Roy and William I. Wood, Ph.D. do hereby declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by Holtzman *et al.*, U.S. Published Patent Application 20020028508, with effective priority date April 23, 1998 (09/065,363), and Sheppard *et al.*, U.S. Published Patent Application 20030166907, with effective priority date June 18, 1997 (09/050,143)
3. The polypeptide comprising the amino acid sequence of residues 35-273 of SEQ ID NO:506 and the nucleic acid sequence of nucleotides 603-1220 of SEQ ID NO:505 in the above-identified application in the United States were sequenced and cloned prior to June 18, 1997.
4. At the time the above polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA encoding the polypeptide comprising the amino acid sequence of residues 35-273 of SEQ ID NO:506.

5. At the time the above polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, was responsible for overseeing the sequencing of nucleotides encoding novel polypeptides, including the polypeptide having the amino acid sequence of residues 35-273 of SEQ ID NO: 506 in the above-identified application.
6. At the time the nucleotide encoding the above polypeptide was cloned and sequenced, one of the inventors, William I. Wood, was responsible for overseeing the homology searches for novel polypeptides, including that for the polypeptide having the amino acid sequence of residues 35-273 of SEQ ID NO: 506 in the above-identified application.
7. The PRO213 polypeptide shown in SEQ ID NO:2 is encoded by a cDNA sequence referred to as DNA30943-1163 and shown in Figure 2 of the above-identified application.
8. A cDNA sequence DNA30943-1163 is identified as SEQ ID NO:1 and shown in Figure 1 of the above-identified application.
9. The PRO213 nucleic acid sequence was found to contain sequence errors. Therefore, the PRO213 nucleic acid sequence was resequenced and designated as 213-1 nucleic acid sequence and the translated polypeptide was designated as the PRO213-1 polypeptide.
10. The PRO213-1 polypeptide shown in SEQ ID NO:506 is encoded by a cDNA sequence referred to as DNA30943-1-1163-1 and shown in Figure 213 of the above-identified application..
11. A cDNA sequence DNA30943-1-1163-1 is identified as SEQ ID NO:505 and shown in Figure 212 of the above-identified application.
12. Copies of the pages from the GSeqEdit database and GenenGenes database which report the cloning, sequencing and functional data for the PRO213 and PRO213-1 polypeptide sequences, including its homology to human gas6, as well as the cloning, and sequencing data for the nucleic acid sequence encoding the PRO213 and PRO213-1 polypeptides are attached to this declaration (with the dates redacted) as Exhibit A.

13. The GSeqEdit report shows the full-length nucleic acid sequence for DNA30943-1-1163-1 and the full-length PRO213-1 polypeptide encoded by DNA30943-1-1163-1. The full-length nucleic acid sequence for PRO213-1 (DNA30943-1-1163-1) shown in the report includes the sequence corrections made to PRO213 (DNA30943-1163) indicated below the sequence, for example, as seen on page 5 of the report. The full-length nucleic acid sequence for PRO213 (DNA30943-1163) is the sequence shown in the GSeqEdit report without the indicated corrections.
14. The amino acid sequence of residues 1-49 of PRO213 is shown in GSeqEdit report on pages 4-5. The amino acid sequence of PRO213-1 shown in GSeqEdit report starts on page 4 and continues onto the following pages. On page 5, the top sequence is the PRO213 polypeptide sequence and the bottom sequence is the PRO213-1 polypeptide sequence.
15. The amino acid sequence starting on page 6 of the GSeqEdit is identical for both the PRO213 and PRO213-1 polypeptides. Amino acid residue number 35, shown on page 6 of the GSeqEdit report, indicates the continuous numbering of PRO213-1 polypeptide sequence from the previous page. The first amino acid on page 6 corresponds to amino acid 57 of the PRO213 polypeptide.
16. The amino acid sequence of residues 35-273 of SEQ ID NO:506 shown in Figure 213 of the above-identified application is 239 amino acids long, and is identical to the amino acid sequence of residues 57-295 of SEQ ID NO:2 shown in Figure 2 of the above-identified application.
17. The nucleic acid sequence encoding residues 35-273 of SEQ ID NO: 506 comprises residues 501-1220 of SEQ ID NO:505 in Figure 212 of the above-identified application. The nucleic acid sequence comprising residues 501-1220 of SEQ ID NO:505 is 720 nucleotides long and it includes a stop codon.
18. The portion of the PRO213 polypeptide, which is identical to the portion of the PRO213-1 polypeptide encoded by the nucleic acid sequence comprising residues 501-1220 of SEQ ID NO:505, is significantly homologous with the human growth arrest-specific 6 (gas6) protein.

19. Both DNA30943-1163 cDNA sequence and the PRO213 polypeptide encoded by DNA30943-1163 were obtained prior to June 18, 1997. Furthermore, the homology of PRO213 to human gas6 was obtained prior to June 18, 1997.
20. The DNA sequence of nucleotides 606 to 1223 of SEQ ID NO:1 is identical to nucleotides 603 to 1220 of DNA30943-1-1163-1 sequence shown in the GSeqEdit report. Further, the DNA sequences of nucleotides 606 to 1223 of SEQ ID NO:1 and nucleotides 603 to 1220 of DNA30943-1-1163-1 shown in the GSeqEdit report are identical to that of nucleotides 603-1220 of SEQ ID NO:505 disclosed in the above-identified application.
21. The beginning of the cDNA sequence corresponding to nucleotides 501-1220 of SEQ ID NO:505 in the above-identified application is shown on page 6 of the GSeqEdit database report. The location of nucleotide 501 of SEQ ID:505, which corresponds to nucleotide 501 of DNA30943-1-1163-1 shown in the GSeqEdit report, is marked with an arrow. The location of nucleotide 603 of SEQ ID:505, which corresponds to nucleotide 603 of DNA30943-1-1163-1 shown on page 7 of the GSeqEdit report, is marked with an arrow. The location of the nucleotide 1220 of SEQ ID NO:505, which corresponds to nucleotide 1220 of DNA30943-1-1163-1 shown on page 12 of the GSeqEdit report, is marked with an arrow.
22. The amino acid residues in the GSeqEdit report which correspond to residues 35 to 273 of SEQ ID NO: 506 are shown starting on page 6 (indicated by an arrow) to page 12 of the report.
23. Exhibit A clearly shows that amino acids residues 35 to 273 of SEQ ID NO: 506 and the nucleic acid residues 603-1220 of SEQ ID NO: 505 disclosed in the above-identified application, as well as the homology of the polypeptide to human gas6, were obtained prior to June 18, 1997.

24. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Audrey Goddard, Ph.D.


Date

Paul J. Godowski, Ph.D.

Date

Austin Gurney, Ph.D.

Date


Margaret A. Roy


Date

William I. Wood, Ph.D.

Date

SV 2094833 v1
5/1/05 2:23 PM (39780.2630)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Goddard et al. Attorney's Docket No: 39780-2630P1C4
Serial No: 09/978,191 Group Art Unit: 1646
Filed: October 15, 2001 Examiner: O'Hara, Eileen B.
For: **SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**DECLARATION OF AUDREY GODDARD, Ph.D.,
PAUL J. GODOWSKI, Ph.D., AUSTIN GURNEY, Ph.D., MARGARET A. ROY
and WILLIAM I. WOOD, Ph.D. UNDER 37 CFR 1.131**

We, Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., Austin Gurney, Ph.D., Margaret Roy and William I. Wood, Ph.D. do hereby declare and say as follows:

1. We are the inventors of the above-identified application.
2. We have read and understood the claims pending in this application, and are aware that the claims have been rejected as anticipated by Holtzman *et al.*, U.S. Published Patent Application 20020028508, with effective priority date April 23, 1998 (09/065,363), and Sheppard *et al.*, U.S. Published Patent Application 20030166907, with effective priority date June 18, 1997 (09/050,143)
3. The polypeptide comprising the amino acid sequence of residues 35-273 of SEQ ID NO:506 and the nucleic acid sequence of nucleotides 603-1220 of SEQ ID NO:505 in the above-identified application in the United States were sequenced and cloned prior to June 18, 1997.
4. At the time the above polypeptide was cloned and sequenced, one of the inventors, Austin Gurney, was responsible for overseeing the cloning of cDNAs which encoded novel polypeptides, including the cDNA encoding the polypeptide comprising the amino acid sequence of residues 35-273 of SEQ ID NO:506.

5. At the time the above polypeptide was cloned and sequenced, one of the inventors, Audrey Goddard, was responsible for overseeing the sequencing of nucleotides encoding novel polypeptides, including the polypeptide having the amino acid sequence of residues 35-273 of SEQ ID NO: 506 in the above-identified application.
6. At the time the nucleotide encoding the above polypeptide was cloned and sequenced, one of the inventors, William I. Wood, was responsible for overseeing the homology searches for novel polypeptides, including that for the polypeptide having the amino acid sequence of residues 35-273 of SEQ ID NO: 506 in the above-identified application.
7. The PRO213 polypeptide shown in SEQ ID NO:2 is encoded by a cDNA sequence referred to as DNA30943-1163 and shown in Figure 2 of the above-identified application.
8. A cDNA sequence DNA30943-1163 is identified as SEQ ID NO:1 and shown in Figure 1 of the above-identified application.
9. The PRO213 nucleic acid sequence was found to contain sequence errors. Therefore, the PRO213 nucleic acid sequence was resequenced and designated as 213-1 nucleic acid sequence and the translated polypeptide was designated as the PRO213-1 polypeptide.
10. The PRO213-1 polypeptide shown in SEQ ID NO:506 is encoded by a cDNA sequence referred to as DNA30943-1-1163-1 and shown in Figure 213 of the above-identified application..
11. A cDNA sequence DNA30943-1-1163-1 is identified as SEQ ID NO:505 and shown in Figure 212 of the above-identified application.
12. Copies of the pages from the GSeqEdit database and GenenGenes database which report the cloning, sequencing and functional data for the PRO213 and PRO213-1 polypeptide sequences, including its homology to human gas6, as well as the cloning, and sequencing data for the nucleic acid sequence encoding the PRO213 and PRO213-1 polypeptides are attached to this declaration (with the dates redacted) as Exhibit A.

13. The GSeqEdit report shows the full-length nucleic acid sequence for DNA30943-1-1163-1 and the full-length PRO213-1 polypeptide encoded by DNA30943-1-1163-1. The full-length nucleic acid sequence for PRO213-1 (DNA30943-1-1163-1) shown in the report includes the sequence corrections made to PRO213 (DNA30943-1163) indicated below the sequence, for example, as seen on page 5 of the report. The full-length nucleic acid sequence for PRO213 (DNA30943-1163) is the sequence shown in the GSeqEdit report without the indicated corrections.
14. The amino acid sequence of residues 1-49 of PRO213 is shown in GSeqEdit report on pages 4-5. The amino acid sequence of PRO213-1 shown in GSeqEdit report starts on page 4 and continues onto the following pages. On page 5, the top sequence is the PRO213 polypeptide sequence and the bottom sequence is the PRO213-1 polypeptide sequence.
15. The amino acid sequence starting on page 6 of the GSeqEdit is identical for both the PRO213 and PRO213-1 polypeptides. Amino acid residue number 35, shown on page 6 of the GSeqEdit report, indicates the continuous numbering of PRO213-1 polypeptide sequence from the previous page. The first amino acid on page 6 corresponds to amino acid 57 of the PRO213 polypeptide.
16. The amino acid sequence of residues 35-273 of SEQ ID NO:506 shown in Figure 213 of the above-identified application is 239 amino acids long, and is identical to the amino acid sequence of residues 57-295 of SEQ ID NO:2 shown in Figure 2 of the above-identified application.
17. The nucleic acid sequence encoding residues 35-273 of SEQ ID NO: 506 comprises residues 501-1220 of SEQ ID NO:505 in Figure 212 of the above-identified application. The nucleic acid sequence comprising residues 501-1220 of SEQ ID NO:505 is 720 nucleotides long and it includes a stop codon.
18. The portion of the PRO213 polypeptide, which is identical to the portion of the PRO213-1 polypeptide encoded by the nucleic acid sequence comprising residues 501-1220 of SEQ ID NO:505, is significantly homologous with the human growth arrest-specific 6 (gas6) protein.

19. Both DNA30943-1163 cDNA sequence and the PRO213 polypeptide encoded by DNA30943-1163 were obtained prior to June 18, 1997. Furthermore, the homology of PRO213 to human gas6 was obtained prior to June 18, 1997.
20. The DNA sequence of nucleotides 606 to 1223 of SEQ ID NO:1 is identical to nucleotides 603 to 1220 of DNA30943-1-1163-1 sequence shown in the GSeqEdit report. Further, the DNA sequences of nucleotides 606 to 1223 of SEQ ID NO:1 and nucleotides 603 to 1220 of DNA30943-1-1163-1 shown in the GSeqEdit report are identical to that of nucleotides 603-1220 of SEQ ID NO:505 disclosed in the above-identified application.
21. The beginning of the cDNA sequence corresponding to nucleotides 501-1220 of SEQ ID NO:505 in the above-identified application is shown on page 6 of the GSeqEdit database report. The location of nucleotide 501 of SEQ ID:505, which corresponds to nucleotide 501 of DNA30943-1-1163-1 shown in the GSeqEdit report, is marked with an arrow. The location of nucleotide 603 of SEQ ID:505, which corresponds to nucleotide 603 of DNA30943-1-1163-1 shown on page 7 of the GSeqEdit report, is marked with an arrow. The location of the nucleotide 1220 of SEQ ID NO:505, which corresponds to nucleotide 1220 of DNA30943-1-1163-1 shown on page 12 of the GSeqEdit report, is marked with an arrow.
22. The amino acid residues in the GSeqEdit report which correspond to residues 35 to 273 of SEQ ID NO: 506 are shown starting on page 6 (indicated by an arrow) to page 12 of the report.
23. Exhibit A clearly shows that amino acids residues 35 to 273 of SEQ ID NO: 506 and the nucleic acid residues 603-1220 of SEQ ID NO: 505 disclosed in the above-identified application, as well as the homology of the polypeptide to human gas6, were obtained prior to June 18, 1997.

24. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.


Date

Austin Gurney, Ph.D.


Date

Margaret A. Roy

Date



William I. Wood, Ph.D.



Date

SV 2094833 v1
4/29/05 10:13 AM (39780.2630)

```

>Wednesday, [REDACTED]
>DNA30943 [Full]
>2077 sites [All Sites]
>[REDACTED] :DNA30943], Jean
> no stop in front

```

```

scrFI[M.hpaII-]
ncli
mapI
hpaII mnlI
dsav sau3AI rnaI
bsSKI mboI/ndelII(dam-)
xmaI/papAI maeI
snaI dpuII(dam-)
scrFI[M.hpaII-]
ncli dpuI(dam+)
dsav nlaIV xbaI sau3AI.taqI
tspS09I[M.ecoRI-] bfaI mboI/ndelII(dam-)
ecorI bssKI bstYI/xhoII dpuII(dam-)
apoI bsaJI bamHI bpy188III mnlI
taqI[M.claI-] bsaJI alwI(dam-) dpuI(dam+) drdI bsh1236I mmoI hpyCH4
clai/bspI06 avai[M.hpaII-] alwI(dam-) taqI mluI ecli cae8I bsgI
bspDI(dam-) bsaJI alwI(dam-) bstYI/xhoII mnlI afIII acII aluI haeIII/palI
1 CCAGGTCCAA CTCACCTCG GTCTCTGGA TGAATTC CCAGGATCCT CTAGAGATCC CTCGACCTCG ACCCAGCGGT CCGCCAGCT GCCCTGCAC
GCTCCAGGTT GACGTGAGC CAGATAGCT AACTTAAGG GCCCTAGGA GATCTTAGG GAGCTGAGC TGGGTGCCA GCGGTTGCA CCGGACGTG

```


→


```

tsei
mmol
fnu4HI/bsoFI
haeIII/palI
eaeI[dcn-]
cfrI fnu4HI/bsoFI
scrFI[dcn-] hpyCH4V
pspGI bbvI tsei afcI
mvaI mspALI/nspBII pscI
ecorIII[dcn-] fnu4HI/bsoFI
dsaV[dcn-] bbvI sse8387I
bscNI acII mspALI/nspBII tsp45I
bsaKI[dcn-] acII sbfI fckI acII maeIII
apYI[dcn+] fnu4HI/bsoFI baf5I hphI bs
bbvI cac8I acII hpaII mnlI aluI
701 CTGTGAGCA GCALMIGCC AGCCGCCATG CCGAAGGA GGGAGCTGTG TCACGCTGG CCCTGCGCG TGCCTGCAG GATGGCGGGG TGACACTGC
GACACCTCGT CGTTATACGG TCGGCGGCTAC GGCCTTGCTT CCTCGACAC AGGTGGACC GCGGACGGCG AGGGAGCTC CTACCGCCC ACTGTGAGC
102 C G A A I C Q P P C R N G G S C Y Q P G R C R C P A G R R G D T C

```

```

tsei alwNI[dcn-]
fnu4HI/bsoFI mspI
bbvI hpaII nlaIV
hlnPI sfanI naeI/ngoMI bsrI
bsmI tspRI mnlI hhaI/cfoI cfrIOL/bstrFI banI tspRI bspI286
fckI btsI maeI fnu4HI/bsoFI haeII hpyCH4V cac8I maeIII bsrI bmyI
hpy188I bst5I hpyCH4V bfaI acII bsmFI afeI/eco47III acII alw26I/bsmAI bslI mnlI
801 CAGTCAGATG TGAATGATG CAGTGCCTAGG AGGGCGGGCT GTCCCGACGG CTGCATGAC ACCGCGCGCA GTTACTGTG CCACTGTGTG GAGGGGACA
GTCAAGCTAC ACCTACTAC GTACAGATCC TCCCGCGCGA CAGGGGTGCG GACGTAGTG TGCGGCGCGT CAATGACAC GGTACACACC CTCCCGGTGT
135 Q S D V D E C S A R R G G C P Q R C I N T A G S Y W C Q C W E G H S

```


hgiA-/aspEI
 bspi286
 bsiHKA1

kmvI

scr3-(dcm-)

tseI pspG:

fnu4HI/bscFI

bov- nvaI hpyCH4V

mspi ecorII(dcm-)

hpaII dsaV(dcm-)

scrFI(M.hpaII-) apaII/snoI

ncII bscNI

dsaV baskI(dcm-)

bssKI apyI(dcm-)

bssAI mnlI alw4II/snoI

acII

fnu4HI/bscFI

ncrI pIeI

eagI/xmaII(ec)XI

eaeI mlyI

alvi haeII/paII

tseI cfrI hlnfi(M.taqi-)

fnu4HI/bscFI taqi ddeI

bvI bsiBI sfanI bspcNI

mnlI

bseRI

bpml/gsuI(dcm-)

scrFI(dcm-)

pspGI tseI avaiI

nvaI fnu4HI/bscFI

ecorII(dcm-) ppuMI

dsaV(dcm-) pvuII(M.H-)

bseNI bvi nIaIV

bssKI(dcm-) alvi eco0109I/dr

apyI(dcm+) mspAII/mspBII

1101 GACCCCEGCA ECCTCCTGGT GCACTCCCTTC CAGCAGCTCG GCCGCATCGA CTCCTCGAGC GAGCAGATT CCTTCCTGGA GGAACAGCTG GGGTCTGCT
 CTGGGCGCGT CGGAGGACCA CGTGAAGAAG GTGCTGAGC CGGCTAGCT GAGGACTCG CTCGTAAAG GGAAGACCT CCTGCTGAC CCCAGAGCA
 235 C C G S T L V H S F Q Q L G R I D S L S E Q I S F L E E Q L G S C S

		scrfI(dcm-)							
		pspGI							
		mvaI							
		ecorII(dcm-)							
		dsaV(dcm-)							
		bstNI		mnoI		tseI			
		bsI		bspI286		fmv4HI/bscFI			
	cpv.88III					bbvI			
	bssS-		mnoI bssKI(dcm-)	bmyI					
	p-eI tsp45I		hinfI apyI(dcm+)	banII		hpyCH4V		nlaiIII	hpyI
	mlyI maeIII		hhaI/cfo-	ddeI		sfiCI		nspHI	sa96I
	hinc- ↓		haeII bsaXI	bspcNI mnlI	fmv4HI/bscFI	nlaiIII		bstXI	avaII
						acII pscI(M.HI-)		mnoI nspI	nlaiV
1201	CCTGCACAGA AGACTGCTGA CTGCCCAAGC CCCAGGCTG GACTGAGCC CTACAGCCGC CCTGCAGCCC CCATGCCCT GCCCAACATG CTGGGGGTC								
	EGAGCTCTT TCTGAGCACT GACGCTCCG GGGGTCCAC CTGACTCGGG GAGTCCGGC GGAAGTCGGG GGTACGGGA CAGGTGTAC GACCCCAAG								
263	C X K D S O								

sa961

nlav

avai

sandi

ppmi

nlav

ecoolf9:/draii

scrfl[dcn-]

pspc: nlali-

mval styi

ecori[dcn-]

dsav[dcn-]

bstnt ncoi

bsski[dcn-]

bsavl daai

apyi[dcn+]

nlav bsm3i bigl/bstdsi

alav opml/gu[dcn-] bsavl

1501 acctccctgc tgcagcctgc gaccacatgc acagaccagc caeccccagc

tcgagcagc acctgcgacc ctgcgacgc tctccgcgtc gtccggcctc

gcagccacc ccgagtcacc cccgagcgc gactggggt ctgttattt

*edit 7 to C -godarda

*deleted a C -godarda

mspi

tsei bpaii

fnu4hi/bsofi

bvvi scrfl[m.bpaii-]

scrfl[dcn-]

pspci ncli

mval dsav

ecori[dcn-]

dsav[dcn-]

bstnt bsski

bsski[dcn-] mcli

nlav bsm3i

alav opml/gu[dcn-] bsavl

1501 acctccctgc tgcagcctgc gaccacatgc acagaccagc caeccccagc

tcgagcagc acctgcgacc ctgcgacgc tctccgcgtc gtccggcctc

gcagccacc ccgagtcacc cccgagcgc gactggggt ctgttattt

*edit 7 to C -godarda

*deleted a C -godarda

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

tspr

lmal
mael

pie:

acii nlyi

fnu4HI/bsoFI

maeIII/pali

mcrl hndfi

eaqi/xmaIII/ecXI

eacl thal xbal pieI

cfri fnuDI/avni

bsiEI drdi

notI bstUI hpy188III

fnu4HI/bsoFI

acii bsn1236I

hndII(M.taql-)

hndIII bgiI(M.iae

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

sa

s-yI

acii ha

muoi nlaII

fnu4HI/bso

sfil ncoI(M

dsai

eacl btgi/b

cfri bsauI

hndIII/pali

hndII(M.taql-)

hndIII bgiI(M.iae

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

CGGCGGCTAC

tail

maeII/hpyCH4IV

1601 AATGAAACGT

TTACTTGC

CTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

TTTTT

alvi

tsei

fnu4HI/bsoFI

dbvi psiI

hpyCH4V

maeIII

1701 GCCCAACTG TTATGAG CTATATG TTACAAT

CGGCTGAC AATTAACGT GACATACC AATGTTA

> .length: 1738

acc65-(GGTACC):

1447

DNA30943

GENE/GENES										Additional Resources	
GENE VIEWER	GENE	FAST	MAP	GENEVIEW						Find C New C Update	
GENE VIEWER	GENE	FAST	RNA	LIB	FLS	FAST				SELECT	
GENE VIEWER	GENE	FAST	EXP	SUN	LOC	FAST					

DNA30943

DNA Info [Project DNA28735](#)

Is Primarydna ☐

Source Info 187 FLS 339 [LB25](#) [RNA22](#) [SRC18](#) Human Fetal Lung

Gene Info [PRO211](#) Human Eglf7 (VEMF) Non-Secreted UNQ187

Gene Annotation

Genome Mapping Run Geode

Affy [HGU133A 218825_at](#)

[HGU133P 218825_at](#)

[HGU95C 48695_at](#)

[Hu35KA R39467_f_at](#)

[Hu35KC RC_N74688_f_at](#)

[Hu35KD RC_N70081_at](#)

[HuGenet1 NM_016215_at](#)

[MOE430A 1421335_a_at](#), [1435823_x_at](#), [1451427_a_at](#), [1451428_x_at](#)

[MOE430P 1421335_a_at](#), [1435823_x_at](#), [1451427_a_at](#), [1451428_x_at](#)

[Rat230v2 1370402_at](#), [1374570_at](#), [1393427_s_at](#)

Agilent [H1Av2 A_23_P123785](#)

[H1A A_23_P123785](#)

[H1Av2 A_23_P123785](#)

[H1B A_32_P210842](#), [A_32_P300230](#)

[M1A A_51_P315841](#)

[WHG A_32_P210842](#)

FANTOM Mouse:[9610012G11](#)

Human:[AB125649](#), [AF188111](#), [AL612735](#), [AY358901](#), [AY358902](#), [AY358903](#), [BC012377](#)

GenBank Mouse:[AF184973](#), [AK002601](#), [AY239289](#), [AY239290](#), [AY309459](#), [BC024610](#)

GeneHub Human:[GENE7437](#)

Mouse:[MGENE1470](#)

INCYFL Human:[931424.FL1_0](#), [931424.FL3_0](#)

Human:[416842.1](#), [416842.13](#), [416842.17](#), [416842.58](#), [416842.68](#), [416842.82](#), [416842.84](#), [416842.87](#), [416842.88](#)

[416842.69](#), [416842.70](#), [416842.72](#), [416842.74](#), [884053.1](#)

LocustLink Human:[51162](#)

Mouse:[333158](#)

MGI Mouse:[2448823](#)

OMIM Human:[808582](#)

Proteome Human:[NP_958854.1](#)

Mouse:[NP_942017.1](#)

RefSeq Human:[NM_016215](#), [NM_201446](#)

Mouse:[NM_178444](#), [NM_198724](#), [NM_198725](#)

UniGene Human:[Hs.91481](#)

Mouse:[Mm.268933](#)

General Info

Lab Name 28735.2

Insert Name undetermined

Generated By Full Length Screen

Type of DNA FLS

Insert ID Novel

Action Drp Not FL

Concentration

Origene Plate

Construct Info

Tag

Bases to Sequence

Insert (Digest) Size(bp) 1600

Reverse Size(bp) 1

Internal Size(bp) 239

Cut Size(bp)

Vector

Interest not reviewed

Origene Cloned

Origene Well

Exp System

Sequence Status

DNA30943

Antibody Info No antibody info

Other info ☐ In Situ image available☐ TaqMan Hit☐ Transgenic Animal Model

OL15288
 OL15289
 OL15290
 OL15572 30943.f1
 OL15573 30943.f2
 Oligos OL17839 30943.tm.f1
 OL17840 30943.tm.r1
 OL17841 30943.tm.p1
 OL17845 30943.tm.f3
 OL17846 30943.tm.r3
 OL17847 30943.tm.p3

Comments

Login	Date Entered	Annotation
dtb		homolog to an unknown human protein and to gas6. The mouse protein with 40 % identity clearly has a signal sequence whereas this clone does not. I think the clone is suspect.-ALG
goddarda		Sequencing in clone 64908 allowed us to correct three sequencing errors in 30943 which lie in the 5' UTR of the gene. However the presence of these errors caused us to identify the wrong 5' end of the ORF in the gene. -goddarda
goddarda		Sequence was flagged as poor quality during proofreading. Tried to rerun reactions with Big DYE chemistry, but too little DNA - signal unreadable. Requested more DNA. Never received -goddarda
goddarda		amplified colon tumors and to a lesser extent in lung tumors- TaqMan assay
jean		Clone 30943 from plasmid inventory plate is verified correct through partial sequencing

Legal Status No legal status

Status

Scientist Daryl Baldwin

Notebook 0

Page

Storage Location

Box

Slot

Inventory Status

Others ☐ Sent to pLASMID Archive
☐ Clone Verified

Date Entered

Date Updated

Date Completed

Date Canceled

Cancel Reason

Clone Status not reviewed

Sequence Status

Project Member

No Project member generated

FLS FLSDNA

No FLS, FLSDNA generated

Exp Construct

EXP

Lab Name

Construct DNA

System

EXP7559

Protein Engineering

DNA346527

Baculovirus

ABI

ABI Run.Lane

Date Sequenced

ABI Plate

ABI512.31

ABI512.32

ABI512.33

ABI512.34

ABI512.35

ABI812.30

ABI812.31

ABI1055.40

ABI1055.41

ABI2530.13

1252

MA Plate

MA Plate

Well Num

Well Location

Date

Type Plate

PLT129

25

C1

08/11/1999

Inventory

Print Run

No Print run generated

XPT